Definium Therapeutics(DFTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DFTX Definium Therapeutics

交易中 09-15 12:06:04 EDT

37.72

-2.53

-6.29%

最高40.35	最低37.32	成交量174.92万
今开40.21	昨收40.25	日振幅7.53%
总市值50.68亿	流通市值49.46亿	总股本1.34亿
成交额6,692万	换手率1.33%	流通股本1.31亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":37.72,"timestamp":1789488360875,"preClose":40.25,"halted":0,"volume":1749209,"delay":0,"changeRate":-0.06285714285714289,"floatShares":131114280,"shares":134366950,"eps":-3.482311,"marketStatus":"交易中","change":-2.53,"latestTime":"09-15 12:06:04 EDT","open":40.21,"high":40.35,"low":37.32,"amount":66922911.915013,"amplitude":0.07528,"askPrice":37.74,"askSize":100,"bidPrice":37.7,"bidSize":124,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":40.25,"preHourTrading":{"tag":"盘前","latestPrice":40.21,"preClose":40.25,"latestTime":"09:29 EDT","volume":3384,"amount":136621.95112800002,"timestamp":1789478999999,"change":-0.04,"changeRate":-0.000994,"amplitude":0.017888},"postHourTrading":{"tag":"盘后","latestPrice":40.15,"preClose":40.25,"latestTime":"19:59 EDT","volume":349560,"amount":14069166.9314,"timestamp":1789430362557,"change":-0.1,"changeRate":-0.002484,"amplitude":0.007759},"volumeRatio":1.642702,"impliedVol":0.6878,"impliedVolPercentile":0.0241},"requestUrl":"/m/hq/s/DFTX/tweets","defaultTab":"tweets","newsList":[{"id":"1145365920","title":"Definium Therapeutics股价盘前飙升20%，其LSD类抗焦虑药物在第二项晚期研究中再次取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=1145365920","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145365920?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:33","pubTimestamp":1789385589,"startTime":"0","endTime":"0","summary":"Definium Therapeutics的股价在盘前交易中大幅上涨20%，这一跃升的背后，是该公司基于LSD研发的抗焦虑药物在第二项关键性后期临床试验中再次交出了积极答卷。此番捷报频传，无疑为市场注入了强心剂，投资者信心随之显著提振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174385904","title":"Definium Therapeutics：DT120口崩片III期全景研究在广泛性焦虑障碍中达成主要及关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1174385904","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174385904?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:00","pubTimestamp":1789383614,"startTime":"0","endTime":"0","summary":"Definium Therapeutics今日宣布，其评估DT120口崩片治疗广泛性焦虑障碍的III期PANORAMA研究，已成功达到主要终点及关键次要终点。这一里程碑式的成果，为该公司在焦虑症治疗领域的布局注入了强劲动力。Definium Therapeutics表示，详细的完整研究数据将在即将召开的医学会议上进行展示，并计划基于这些发现，积极与美国食品药品监督管理局等监管机构沟通，推进该药物的注册上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107633829","title":"Definium Therapeutics：DT120口腔崩解片100微克总体耐受性良好，安全性特征一致，未现新型安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1107633829","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107633829?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:00","pubTimestamp":1789383611,"startTime":"0","endTime":"0","summary":"Definium Therapeutics近日公布，其研发的DT120口腔崩解片在100微克剂量下展现出总体良好的耐受性。值得注意的是，该药物的安全性特征保持高度一致性，且未出现任何新型安全信号。在临床观察中，受试者对DT120 Odt 100 Mcg的接受度令人鼓舞。Definium Therapeutics的这项发现，不仅印证了该候选药物的潜在价值，同时也为后续更深入的临床研究奠定了坚实基础。安全性特征的一致性，往往意味着更高的可预测性和更低的开发风险。眼下，公司正积极推进该药物的进一步评估工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148441427","title":"Definium Therapeutics：DT120口崩片100微克在12周时显示安慰剂校正的汉密尔顿焦虑量表评分降低5.1分","url":"https://stock-news.laohu8.com/highlight/detail?id=1148441427","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148441427?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:00","pubTimestamp":1789383609,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，其候选药物DT120口崩片（Odt）在100微克剂量下，于治疗第12周时展现出了显著的抗焦虑疗效。具体数据显示，与安慰剂相比，该药物使患者的汉密尔顿焦虑量表评分平均降低了5.1分，这一结果具有临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160872994","title":"Definium Therapeutics将于2026年9月14日公布泛发性焦虑障碍III期Panorama研究的关键结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1160872994","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160872994?lang=zh_cn&edition=full","pubTime":"2026-09-14 05:00","pubTimestamp":1789333236,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，计划于2026年9月14日召开会议，重点讨论其在泛发性焦虑障碍（GAD）领域所进行的III期Panorama研究的顶线结果。这一备受关注的数据发布，将为该候选疗法的疗效与安全性提供关键性证据。公司方面表示，此次披露的结果有望为后续的监管申报及临床开发路径奠定坚实基础。业界普遍预期，这一研究数据不仅关乎Definium自身的管线价值，也可能对整个焦虑障碍治疗领域产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192985516","title":"Definium Therapeutics 焦虑症药物晚期试验达标，盘前股价飙升 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192985516","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192985516?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:45","pubTimestamp":1786535108,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 的股价在盘前交易时段猛涨22%，原因在于该公司针对焦虑症的一款药物成功达成了后期临床试验的核心目标。这一喜讯瞬间点燃了市场热情，投资者纷纷涌入，推动股价大幅上扬。此次试验结果无疑为这家生物技术公司注入了强劲的发展动力，也为其在精神健康领域的布局增添了关键砝码。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143492874","title":"Definium Therapeutics 宣布DT120 Odt针对广泛性焦虑障碍的3期Voyage研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1143492874","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143492874?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:01","pubTimestamp":1786532478,"startTime":"0","endTime":"0","summary":"Definium Therapeutics（DFTX）今日发布重磅消息：其针对广泛性焦虑障碍的DT120 Odt，在3期Voyage研究中录得积极的顶线数据。该研究结果令人振奋，为这款在研疗法带来了新曙光。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168532165","title":"Definium Therapeutics：DT120 Odt 三期Voyage研究达成主要及关键次要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1168532165","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168532165?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:01","pubTimestamp":1786532471,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，其关键药物DT120 Odt的三期临床试验Voyage研究已成功达成主要及关键次要疗效终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159415209","title":"Definium Therapeutics：DT120 Odt 受试者汉密尔顿焦虑量表评分实现统计学显著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1159415209","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159415209?lang=zh_cn&edition=full","pubTime":"2026-08-12 19:00","pubTimestamp":1786532409,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 宣布，其药物 DT120 Odt 在临床试验中取得突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113882972","title":"Definium Therapeutics 启动“焦虑之源”计划，携手医疗提供者深化广泛性焦虑症患者影响及神经生物学认知","url":"https://stock-news.laohu8.com/highlight/detail?id=1113882972","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113882972?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:01","pubTimestamp":1784199702,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 宣布启动一项名为“焦虑之源”的医疗提供者倡议。该计划旨在推动医学界对广泛性焦虑症（GAD）患者所面临的影响及其背后神经生物学机制的理解，以期促进更有效的临床诊疗策略发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182980299","title":"异动解读｜Definium Therapeutics盘前上涨5.1%，DT120三期数据利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1182980299","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182980299?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:46","pubTimestamp":1784191619,"startTime":"0","endTime":"0","summary":"7月16日，Definium Therapeutics盘前上涨5.1%，报48.0美元/股，成交额6.29万美元。随后公司成功完成8.05亿美元增发募资，承销商全额行使超额配售权，募资用于DT120商业化准备及研发推进。RBC Capital将目标价从36美元大幅上调至57美元，维持\"跑赢大盘\"评级，当前股价仍低于该目标价，市场买盘动能延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Definium Therapeutics盘前上涨5.1%，DT120三期数据利好持续发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154657006","title":"异动解读｜Definium Therapeutics夜盘上涨7.03%，DT120三期数据利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1154657006","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154657006?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:47","pubTimestamp":1784162870,"startTime":"0","endTime":"0","summary":"7月16日，Definium Therapeutics夜盘上涨7.03%，报48.87美元/股，成交额1.91万美元。消息面上，公司此前公布其核心候选药物DT120口崩片治疗重度抑郁症的3期EMERGE研究取得积极顶线结果，主要终点及所有关键次要疗效终点均达成，显示出统计学显著性和临床意义的优势。随后公司成功完成8.05亿美元增发募资，承销商全额行使超额配售权。RBC Capital将目标价从36美元大幅上调至57美元，维持\"跑赢大盘\"评级，当前股价仍低于该目标价，市场买盘动能延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127959646","title":"异动解读｜Definium Therapeutics盘后上涨5.04%，报47.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127959646","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127959646?lang=zh_cn&edition=full","pubTime":"2026-07-16 06:57","pubTimestamp":1784156250,"startTime":"0","endTime":"0","summary":"7月16日，Definium Therapeutics盘后上涨5.04%，报47.79美元/股，成交额141.84万美元。Definium Therapeutics所在的制药行业中，个股中，礼来涨0.03%，强生涨0.36%，默沙东涨0.02%，辉瑞跌0.12%，施贵宝跌0.0%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111295043","title":"异动解读｜Definium Therapeutics盘中下跌5.44%，报44.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111295043","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111295043?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:21","pubTimestamp":1783952499,"startTime":"0","endTime":"0","summary":"7月13日，Definium Therapeutics盘中下跌5.44%，报44.47美元/股，成交额1282.29万美元。Definium Therapeutics所在的制药行业中，个股中，礼来跌0.21%，辉瑞涨1.78%，强生涨0.03%，Crinetics Pharmaceuticals涨0.06%，阿斯利康跌1.47%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142071966","title":"异动解读｜Definium Therapeutics盘中下跌5.06%，报46.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142071966","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142071966?lang=zh_cn&edition=full","pubTime":"2026-07-10 21:51","pubTimestamp":1783691501,"startTime":"0","endTime":"0","summary":"7月10日，Definium Therapeutics盘中下跌5.06%，报46.0美元/股，成交额912.92万美元。Definium Therapeutics所在的制药行业中，个股中，礼来跌2.01%，强生涨0.17%，阿斯利康跌2.55%，Crinetics Pharmaceuticals涨0.05%，默沙东跌0.42%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143979950","title":"异动解读｜Definium Therapeutics盘中上涨5.09%，DT120三期临床成功叠加巨额融资提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1143979950","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143979950?lang=zh_cn&edition=full","pubTime":"2026-07-09 23:53","pubTimestamp":1783612422,"startTime":"0","endTime":"0","summary":"7月9日，Definium Therapeutics盘中上涨5.09%，报47.625美元/股，成交额6690.95万美元。消息面上，公司此前公布其核心产品DT120口崩片治疗重度抑郁症的3期EMERGE研究取得积极顶线结果，达到主要终点及所有关键次要疗效终点，安全性特征良好。RBC Capital随之将目标价由36美元大幅上调至57美元，维持\"跑赢大市\"评级。关键临床数据验证叠加充裕资金保障，持续推动股价上行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137042231","title":"异动解读｜Definium Therapeutics盘中下跌5.02%，报44.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137042231","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137042231?lang=zh_cn&edition=full","pubTime":"2026-07-01 23:49","pubTimestamp":1782920992,"startTime":"0","endTime":"0","summary":"7月1日，Definium Therapeutics盘中下跌5.02%，报44.68美元/股，成交额4259.27万美元。Definium Therapeutics所在的制药行业中，个股中，礼来跌0.61%，强生跌0.66%，辉瑞跌0.69%，默沙东跌1.49%，诺和诺德涨2.69%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142122370","title":"异动解读｜Definium Therapeutics盘中上涨5.04%，DT120三期临床积极叠加8亿美元增发落地提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1142122370","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142122370?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:03","pubTimestamp":1782828238,"startTime":"0","endTime":"0","summary":"6月30日，Definium Therapeutics盘中上涨5.04%，报48.84美元/股，成交额2163.95万美元。消息面上，公司近期利好密集释放。随后公司迅速启动增发融资，最终以每股34美元完成约2370万股的扩大规模公开发行，募资总额达8.05亿美元，承销商全额行使超额配售权，反映市场认购需求旺盛。此外，RBC Capital将公司目标价从36美元大幅上调至57美元，维持\"跑赢大盘\"评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160379075","title":"Definium Therapeutics 宣布完成8.05亿美元增发，承销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1160379075","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160379075?lang=zh_cn&edition=full","pubTime":"2026-06-26 04:25","pubTimestamp":1782419116,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 公司已成功完成其增发规模达8.05亿美元的公开募股。此次发行规模较原计划有所扩大，并包含了承销商全额行使购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111531466","title":"异动解读｜Definium Therapeutics盘中上涨9.07%，核心管线3期研究达成主要终点及7亿美元增发定价落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1111531466","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111531466?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:26","pubTimestamp":1782397562,"startTime":"0","endTime":"0","summary":"6月25日，Definium Therapeutics盘中上涨9.07%，报45.595美元/股，成交额9796.98万美元。消息面上，公司于6月22日宣布其候选药物DT120口崩片在治疗重度抑郁症的关键3期EMERGE研究中达成主要终点及所有关键次要疗效终点，显示出统计学显著性和临床意义的改善。随后RBC Capital将目标价从36美元大幅上调至57美元，维持跑赢大盘评级。此外，公司于6月24日完成7亿美元扩大规模包销公开发行定价，每股34美元，募资将用于研发及一般企业用途。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.definiumtx.com;ir.definiumtx.com","stockEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0558},{"period":"3month","weight":0.666},{"period":"6month","weight":1.2817},{"period":"1year","weight":3.2638},{"period":"ytd","weight":2.006}],"compareEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.0199},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.1504},{"period":"1year","weight":0.1574},{"period":"ytd","weight":0.1158}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Definium Therapeutics, Inc.于2010年根据不列颠哥伦比亚省法律成立。他们是一家处于后期阶段的临床生物制药公司，正在开发新的候选产品来治疗大脑健康障碍。他们的使命是通过将科学的严谨性应用于迷幻药，锻造精神病学的新时代，目标是开发可获得的治疗方法，以大规模解锁愈合。他们正在开发一系列针对神经递质通路的创新候选产品，这些通路在大脑健康疾病中发挥着关键作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.136845},{"month":3,"riseRate":0.4,"avgChangeRate":0.072082},{"month":4,"riseRate":0.8,"avgChangeRate":0.037703},{"month":5,"riseRate":0.5,"avgChangeRate":0.01554},{"month":6,"riseRate":0.5,"avgChangeRate":0.064762},{"month":7,"riseRate":0.666667,"avgChangeRate":0.160554},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.090843},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.143488},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Definium Therapeutics(DFTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Definium Therapeutics(DFTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Definium Therapeutics,DFTX,Definium Therapeutics股票,Definium Therapeutics股票老虎,Definium Therapeutics股票老虎国际,Definium Therapeutics行情,Definium Therapeutics股票行情,Definium Therapeutics股价,Definium Therapeutics股市,Definium Therapeutics股票价格,Definium Therapeutics股票交易,Definium Therapeutics股票购买,Definium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Definium Therapeutics(DFTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Definium Therapeutics(DFTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}